Opioid Induced Constipation Treatment
Number of pages: 100 | Report Format: PDF | Published date: May 24, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.15 billion |
|
Revenue Forecast in 2031 |
US$ 1.77 billion |
|
CAGR |
4.85% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug class, Distribution channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global opioid induced constipation treatment market was valued at US$ 1.15 billion in 2022 and is expected to register a revenue CAGR of 4.85% to reach US$ 1,77 billion by 2031.
Opioid Induced Constipation Treatment Market Fundamentals
Opioid induced constipation (OIC) is a common side effect experienced by individuals taking opioid medications for pain management. This condition is characterized by infrequent bowel movements, difficulty passing stools, and discomfort. Fortunately, advancements have been made in treating opioid induced constipation, including the development of targeted medications that specifically address the underlying mechanisms of opioid induced constipation. These medications selectively block the opioid receptors in the gut, alleviating constipation while preserving the pain-relieving effects of opioids. Additionally, combining pharmacological interventions with non-pharmacological approaches such as dietary modifications, increased physical activity, and adequate hydration can enhance treatment outcomes.
The global opioid induced constipation treatment industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the opioid induced constipation treatment market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the opioid induced constipation treatment market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Opioid Induced Constipation Treatment Market Dynamics
The key factor supporting the opioid induced constipation treatment market is its increased demand for pain management. Opioids are primarily prescribed to manage moderate to severe pain in patients with chronic diseases such as cancer. Cancer that has spread locally or has metastasized is typically painful. According to the 2022 estimates by the American Society of Clinical Oncology, pain prevalence increases with disease progression and affects around 64% of patients with advanced cancer. Approximately 45% of all patients with advanced cancer report moderate to severe pain. This increasing demand for opioids has increased the prevalence of opioid induced constipation. In February 2019, the John Wiley Journal stated that opioid induced constipation (OIC) is prevalent among patients receiving opioids for cancer and chronic non-cancer pain. Studies show that it affects 51-87% of cancer patients and 41-57% of patients with chronic non-cancer pain.
Additionally, market players are increasingly introducing generic versions of the drugs in the market. For instance, in January 2021, Par Pharmaceutical, Inc. released the first authorized generic form of Amitiza (lubiprostone; Mallinckrodt). This trend of introducing generic versions of drugs is expected to continue in the future, as it helps to reduce the cost of medications and increase accessibility to patients.
However, the lack of awareness and limited access to healthcare facilities may hinder the market growth in the region. Moreover, the side effects of these drugs and patent expiration are some other restraining factors in the opioid induced constipation treatment market.
Opioid Induced Constipation Treatment Market Ecosystem
Opioid Induced Constipation Treatment Market, by Drug Class
Opioid Induced Constipation Treatment Market, by Distribution Channel
Opioid Induced Constipation Treatment Market by Drug Class
Peripherally acting μ-opioid receptor antagonists segment dominated the global opioid induced constipation treatment market. Furthermore, these medications do not pass the blood-brain barrier and do not interfere with opioid analgesic effects. This makes them an appealing alternative for people who require opioid pain relief but still have opioid induced constipation treatment market. Furthermore, peripherally acting -opioid receptor antagonists are less likely to cause side effects like nausea and vomiting, which are frequent with other opioid induced constipation therapies.
The market segmentation sections provide the opioid induced constipation treatment market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as drug class, distribution channel, and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data also helps identify potential opioid induced constipation treatment market demand opportunities.
Opioid Induced Constipation Treatment Market by Region
North America dominated the global opioid induced constipation treatment market with the highest revenue share. The increasing prevalence of chronic pain conditions and the subsequent rise in opioid prescriptions have contributed to the growth of the opioid induced constipation treatment market in North America. In addition, the aging population and the high incidence of cancer in North America have also played a significant role in driving the demand for these treatments. According to the National Center for Biotechnology Information, approximately 1.9 million reported cancer cases were reported. Among the different types of cancer, breast cancer is the most prevalent and is projected to have about 300,590 new cases in the United States by 2023.
The Asia Pacific region for opioid induced constipation treatment market is expected to show a high revenue CAGR of 5.2% in the forecast years. The increased usage of opioid medications and the prevalence of chronic pain conditions have led to a surge in opioid induced constipation cases. Consequently, higher demand for effective treatments for opioid induced constipation symptoms leads to market expansion.
Based on the regions, the global opioid induced constipation treatment market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of opioid induced constipation treatment industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level opioid induced constipation treatment market overview.
Key Components of the Report
Opioid Induced Constipation Treatment Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Opioid Induced Constipation Treatment Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Opioid induced constipation (OIC) is a common side effect experienced by individuals taking opioid medications for pain management.
The global opioid induced constipation treatment market was valued at US$ 1,158.25 million in 2022.
North America will have the largest opioid induced constipation treatment market size during the forecast period from 2023 to 2031.
The global opioid induced constipation treatment market is expected to register a revenue CAGR of 4.85% during the forecast period from 2023 to 2031.
The global opioid induced constipation treatment market is expected to reach US$ 1,773.86 million by 2031.
The most prominent trend in opioid induced constipation treatment industry is its increased accessibility by introducing generic versions.
Increased demand for opioids in pain management is a prominent opportunity for the global opioid induced constipation treatment market.
The lack of awareness and limited access to healthcare facilities may hinder the market revenue growth in the region.
Major strategies adopted by key market players are product differentiation, cost leadership, and market segmentation. Companies may also focus on expanding their geographic reach, investing in research and development, or forming strategic partnerships with other organizations.
*Insights on financial performance are subject to the availability of information in the public domain